Document:

ex101.htm

    STOCK
      PURCHASE AGREEMENT

    

    

    THIS
      STOCK PURCHASE AGREEMENT (the "Agreement") is entered into on the 13th
      day of December, 2007, by and among U.S.A. Capital Management Group, Inc.,
      a
      Florida corporation (“Buyer”), Ruiz Family Holdings (“Seller”), and Anasazi
      Capital Corp., a Florida corporation (the “Company”).

    

    EXPLANATORY
      STATEMENT

    

    WHEREAS,
      Seller desires to sell, and Buyer desires to acquire, all of the outstanding
      common stock of the Company (the "Common Stock"), on the terms described below;
      and

    

    WHEREAS,
      the Company
      and Buyer desire that Law Offices of Michael H. Hoffman, P.A. continue to serve
      as legal counsel to the Company and provide on-going legal services, including
      advice on corporate and securities law matters.

    

    NOW,
      THEREFORE, in consideration of the premises and the mutual covenants,
      conditions and promises hereinafter set forth, the parties hereto agree as
      follows:

    

    1.  PURCHASE
      AND SALE.

    

    1.1  Shares.  On
      the terms and subject to the conditions herein provided, Seller agrees to sell,
      transfer and assign to Buyer, and Buyer agrees to purchase and acquire from
      Seller, on the Closing Date (as defined in Section 1.4 below), Five Million
      (5,000,000) shares (the “Shares”) of Common Stock, which constitute all of the
      issued and outstanding capital stock of the Company.

    

    1.2  Excluded
      Liabilities.  Buyer will not acquire, and Seller shall pay or
      cause the Company to pay, all of the Company’s liabilities as of the Closing
      Date.

    

    1.3  Purchase
      Price.

    

    (1)  Purchase
      Price.  The aggregate purchase price for the Shares to be sold by
      Seller and to be purchased by Buyer is Thirteen Thousand Five Hundred Dollars
      ($13,500) (the “Purchase Price”), which is payable at the closing of this
      Agreement.

    

    (2)  Manner
      of Payment.  Buyer shall pay the Purchase Price by wire transfer
      of immediately available funds to an account designated by Seller.

    

    
      
        
        

      

      
        -1-

        
          

        

      

      
        
        

      

    

    1.4  Closing;
      Effective Date.  Subject to the satisfaction of the conditions
      stated in Section 6, the closing of the transactions contemplated by this
      Agreement (the “Closing”) shall take place at the Seller's office at 12:00 p.m.
      E.S.T. on the date first above written (the “Closing Date”).

    

    1.5  Transactions
      and Documents at Closing.

    

    (1)  Deliveries
      by Seller and the Company.  At the Closing, Seller and the Company
      shall deliver to Buyer:

    

    
      	
              (1)  

            	
              the
                certificate representing the Shares in proper form for transfer to
                Buyer;

            

    

    

    
      	
              (2)  

            	
              the
                resignation of the Company’s sole officer and
                director;

            

    

    

    
      	
              (3)  

            	
              the
                stock ledger, minute book, corporate seal and books and records of
                the
                Company; and

            

    

    

    
      	
              (4)  

            	
              a
                certified copy of all necessary corporate action approving the Company’s
                execution, delivery and performance of this
                Agreement.

            

    

    

    (2)  Deliveries
      by Buyer.  At the Closing, Buyer shall deliver to
      Seller:

    

    
      	
              (1)  

            	
              payment
                of the Purchase Price; and

            

    

    

    
      	
              (2)  

            	
              a
                certified copy of all necessary corporate action approving Buyer’s
                execution, delivery and performance of this
                Agreement.

            

    

    

    2.  ADDITIONAL
      AGREEMENTS.

    

    2.1  Legal
      Services.  The Company shall continue to engage the Law Offices of
      Michael H. Hoffman, P.A. to serve as legal counsel to the Company and provide
      on-going legal services, including advice on corporate and securities law
      matters.  The term of such engagement shall be for a period of one
      year, commencing on the Closing Date, and ending on the first anniversary of
      the
      Closing Date (the “Term”).  If such engagement is not terminated by
      the Company prior to ninety (90) days before the expiration of the Term (or
      any
      extension thereof), the Term shall automatically be extended for an additional
      one year period.  This automatic extension shall apply to each
      subsequent one year period that the Term is extended.

    

    2.2  Cooperation;
      Further Assurances.  Each of the parties hereto will cooperate
      with the other and execute and deliver to the other parties hereto such other
      instruments and documents, provide such other notices or communications and
      take
      such other actions as may be reasonably requested from time to time by any
      other
      party hereto as necessary to carry out the intended purposes of this
      Agreement.

    

    3.  REPRESENTATIONS,
      COVENANTS AND WARRANTIES OF SELLER AND THE COMPANY.

    

    To
      induce
      Buyer to enter into this Agreement and to consummate the transactions
      contemplated hereby, Seller and the Company represent and warrant to and
      covenant with Buyer as follows:

    

    
      
        
        

      

      
        -2-

        
          

        

      

      
        
        

      

    

    3.1  Organization.  The
      Company is a corporation duly organized, validly existing and in good standing
      under the laws of the State of Florida.  Seller is a general
      partnership validly existing and in good standing under the laws of the State
      of
      Florida.

    

    3.2  Execution;
      No Inconsistent Agreements.

    

    (1)  The
      execution and delivery of this Agreement and the performance of the transactions
      contemplated hereby have been duly and validly authorized and approved by Seller
      and the Company, and this Agreement is a valid and binding agreement of Seller
      and the Company, enforceable against Seller and the Company in accordance with
      its terms.

    

    (2)  The
      execution and performance of this Agreement by Seller does not constitute a
      breach or violation of the organizational or governing documents of Seller
      or
      the Company, or a material default under any of the terms, conditions or
      provisions of (or an act or omission that would give rise to any right of
      termination, cancellation or acceleration under) any agreement or obligation
      to
      which Seller or the Company is a party.

    

    3.3  Title
      to Shares.  Seller shall transfer to Buyer good and valid title to
      the Shares, free and clear of all liens and encumbrances.

    

    4.  REPRESENTATIONS,
      COVENANTS AND WARRANTIES OF BUYER.

    

    To
      induce
      Seller and the Company to enter into this Agreement and to consummate the
      transactions contemplated hereby, Buyer represents and warrants to and covenants
      with Seller and the Company as follows:

    

    4.1  Organization;
      Compliance.   Buyer is a corporation duly organized, validly
      existing and in good standing under the laws of the State of
      Florida.

    

    4.2   Execution;
      No Inconsistent Agreements; Etc.

    

    (1)  The
      execution and delivery of this Agreement and the performance of the transactions
      contemplated hereby have been duly and validly authorized and approved by Buyer
      and this Agreement is a valid and binding agreement of Buyer, enforceable
      against Buyer in accordance with its terms.

    

    (2)  The
      execution and delivery of this Agreement by Buyer does not, and the consummation
      of the transactions contemplated hereby will not, constitute a breach or
      violation under any of the terms, conditions or provisions of (or an act or
      omission that would give rise to any right of termination, cancellation or
      acceleration under) any agreement or obligation to which Buyer is a
      party.

    

    4.3  Investment
      Representation.  Buyer understands and acknowledges that (a) the
      Shares have not been registered under the Securities Act of 1933, as amended
      (the “Securities Act”), or under any state securities laws in reliance upon
      exemptions provided thereunder and that the Shares may not be transferred or
      sold except pursuant to the registration provisions of the Securities Act or
      pursuant to an applicable exemption therefrom and pursuant to state securities
      laws and regulations, as applicable, and (b) the representations and warranties
      contained herein are being relied upon by the Company and Seller as a basis
      for
      the exemption for the transfer of the Shares pursuant to this Agreement under
      the registration requirements of the Securities Act and any applicable state
      securities laws.  Buyer is acquiring the Shares for Buyer's own
      account for the purpose of investment and not with a view to, or for sale in
      connection with, any distribution thereof in violation of the Securities
      Act.  Buyer has had the opportunity to review the books and records of
      the Company and has been furnished or provided access to such relevant
      information that Buyer has requested.  Buyer is knowledgeable,
      sophisticated and experienced in business and financial matters of the type
      contemplated by this Agreement and is able to bear the risks associated with
      an
      investment in the Company.  Buyer has considered the investment in the
      Shares and has had an opportunity to ask questions of and receive answers from
      the sole officer and director of the Company about the Shares and the business
      and financial condition of the Company sufficient to enable it to evaluate
      the
      risks and merits of its investment in the Company.

    

    
      
        
        

      

      
        -3-

        
          

        

      

      
        
        

      

    

    4.4  Status
      of Buyer.  Buyer is an “accredited investor" within the meaning of
      Rule 501 promulgated under the Securities Act.

    

    5.  BUYER'S
      ACCESS TO INFORMATION AND ASSETS.  Buyer and its authorized
      representatives, at Buyer’s own expense, shall have access to the books,
      records, employees, counsel, accountants, and other representatives of the
      Company at all times reasonably requested by Buyer for the purpose of conducting
      an investigation of the Company's financial condition, corporate status,
      operations, business, assets and properties.

    

    

    6.  CLOSING
      CONDITIONS.

    

    6.1  Conditions
      to Obligations of Seller.  The obligations of Seller to carry out
      the transactions contemplated by this Agreement are subject, at the option
      of
      Seller, to the following conditions:

    

    (1)  Buyer
      shall have furnished Seller with a certified copy of all necessary corporate
      action on its behalf approving its execution, delivery and performance of this
      Agreement.

    

    (2)  All
      representations and warranties of Buyer contained in this Agreement shall be
      true and correct in all material respects at and as of the Closing, as if such
      representations and warranties were made at and as of the Closing, and Buyer
      shall have performed and satisfied in all material respects all covenants and
      agreements required by this Agreement to be performed and satisfied by Buyer
      at
      or prior to the Closing; provided, however, that Seller shall not be entitled
      to
      refuse to consummate the transactions contemplated by this Agreement in reliance
      upon its own breach or failure to perform.

    

    (3)  Buyer
      shall have executed and delivered to Seller the documents referred to in Section
      1.5.2.2.

    

    6.2  Conditions
      to Obligations of Buyer.  The obligations of Buyer to carry out
      the transactions contemplated by this Agreement are subject, at the option
      of
      Buyer, to the satisfaction of the following conditions:

    

    (1)  The
      Company shall have furnished Buyer with a certified copy of all necessary
      corporate action on its behalf approving its execution, delivery and performance
      of this Agreement.

    

    (2)  All
      representations and warranties of Seller and the Company contained in this
      Agreement shall be true and correct in all material respects at and as of the
      Closing, as if such representations and warranties were made at and as of the
      Closing, and Seller and the Company shall have performed and satisfied in all
      material respects all agreements and covenants required by this Agreement to
      be
      performed and satisfied by Seller and the Company at or prior to the Closing;
      provided, however, that Buyer shall not be entitled to refuse to consummate
      the
      transactions contemplated by this Agreement in reliance upon its own breach
      or
      failure to perform.

    

    (3)  Seller
      and the Company shall have executed and delivered to Buyer the documents
      referred to in Section 1.5.1.

    

    
      
        
        

      

      
        -4-

        
          

        

      

      
        
        

      

    

    7.  MISCELLANEOUS.

    

    7.1  Notices.

    

    (1)  All
      notices, requests, demands, or other communications required or permitted
      hereunder shall be in writing and shall be deemed to have been duly given upon
      receipt if delivered in person, one (1) business day after the date of mailing
      by Federal Express or other reputable overnight courier service or upon the
      expiration of three (3) days after the date of posting, if mailed by certified
      mail return receipt requested, postage prepaid, to the parties at the following
      addresses:

     

    (i)  If
      to Seller or
      Company:                
Ruiz Family Holdings

    701
      Scott
      Street

    San
      Francisco, California 94117

    

    
      	
               

            	
              (ii)  If
                to Buyer:

            	
              U.S.A.
                Capital Management Group, Inc.

            

    

    18101
      Von
      Karman Avenue, Suite 330

    Irvine,
      California  92612

       

    

    (2)  Any
      party
      may change the address to which notices, requests, demands or other
      communications to such party shall be delivered or mailed by giving notice
      thereof to the other parties hereto in the manner provided herein.

    

    7.2  Counterparts;
      Entire Agreement.  This Agreement may be executed in any number of
      counterparts, each of which shall be deemed an original, and all of which shall
      constitute one and the same agreement.  This Agreement supersedes all
      prior discussions and agreements between the parties with respect to the subject
      matter hereof, and this Agreement contains the sole and entire agreement among
      the parties with respect to the matters covered hereby.  This
      Agreement shall not be altered or amended except by an instrument in writing
      signed by or on behalf of all of the parties hereto.

    

    7.3  Governing
      Law.  The validity and effect of this Agreement shall be governed
      by and construed and enforced in accordance with the laws of the State of
      Florida.

    

    7.4  Successors
      and Assigns; Assignment.  This Agreement shall be binding upon and
      shall inure to the benefit of the parties hereto and their respective heirs,
      executors, legal representatives, and successors; provided, however, that no
      party hereto may assign this Agreement or any of its rights hereunder, in whole
      or in part, except upon the prior written consent of the other parties
      hereto.

     

    

    [SIGNATURES
      CONTINUED ON THE FOLLOWING PAGE]

    
      
        
        

      

      
        -5-

        
          

        

      

      
        
        

      

    

    

    IN
      WITNESS WHEREOF, the parties have executed this Agreement on the date
      first above written.

    SELLER:

    

    RUIZ
      FAMILY HOLDINGS

    

    

    By:           /s/
      Olivia
      Ruiz                                                                

         Olivia
      Ruiz, General Partner

    

    COMPANY:

    

    ANASAZI
      CAPITAL CORP.

    

    

    By:           /s/
      Olivia
      Ruiz                                                                

         Olivia
      Ruiz, President

    

    BUYER:

    

    U.S.A.
      CAPITAL MANAGEMENT GROUP, INC.

    

    

    By:           /s/
      Paul
      Garcia                                                                

         Paul
      Garcia, President

    

    

    
      
        
        

      

      
        -6-EXHIBIT 10.20

                                                                  EXECUTION COPY

                                LICENSE AGREEMENT

         THIS LICENSE AGREEMENT (this "Agreement"), is made as of this 12th day
of June, 2006 the "Effective Date"), by and between JDA MEDICAL TECHNOLOGIES,
INC. a Maryland corporation with offices located at 6501 Autumn Wind Circle,
Clarksville, Maryland 21029 ("Licensor"), and FOUNTAIN PHARMACEUTICALS, INC., a
Delaware corporation with offices located at 19022 Marksburg Court, Germantown,
Maryland 20874 ("Licensee").

         WHEREAS. Licensor is the exclusive licensee of certain Patent Rights
(as defined herein) relating to the treatment of human diseases;

         WHEREAS. Licensor has the right to grant sublicenses under the Patent
Rights anti desires to rant a license of such rights to Licensee;

         WHEREAS. Licensee intends to develop, manufacture, market and sell the
Licensed Products as defined herein; and

         WHEREAS. Licensee desires to obtain a license to the Patent Rights in
accordance with the terms and conditions of this Agreement.

         NOW THEREFORE in consideration of the mutual covenants and agreements
contained herein and for other good and valuable consideration, the receipt and
sufficiency, of which are hereby acknowledged, the parties agree as follows:

1. Definitions. For purposes of this Agreement, the following words and phrases
shall have he following meanings:

         1.1 "First Commercial Sale" shall mean the initial transfer of a
Licensed Product for compensation by Licensee or its Sublicenses to any third
party. Transfer of a Licensed Product for clinical or other testing occurring
prior to the issuance of any required regulatory approval for sale does not
constitute a First Commercial Sale.

         1.2 "Licensee Improvement" shall mean any invention, discovery,
enhancement, modification or improvement arising out of or resulting from use of
the Patent Rights which is or may be patentable or otherwise protected under
law, made by one or more employees or subcontractors of Licensee: with the
exception of the Licensee Patent Rights Improvements.

         1.3 "Licensee Patent Rights Improvement" shall mean any invention.
modification or discovery, made by one or more employees or subcontractors of
Licensee, which is directly related to the Patent Rights in the Licensed Field,
the practice of which, if unlicensed, would infringe one or more claims of the
Patent Rights, or which has a similar structure to the Patent Rights and
performs a similar function to that described in the Patent Rights in a better
or more economical manner, which is or may be patentable or otherwise protected
under law in each ease that is (i) a composition solely comprised of a Patent
Rights Linker. (ii) methods of using a Patent Rights Linker, or (iii) methods of
manufacturing a Patent Rights Linker.

<PAGE>

         1.4 "Licensed Field of Use" shall mean the human healthcare field.

         1.5 "Licensed Product" shall mean any product or part thereof which:

             (a) is covered, in whole or in part by an issued, valid, unexpired
claim or a pending claim contained in the Patent Rights in the country in which
such product or part thereof is made, used, leased, offered for sale, sold or
imported:

             (b) is made by a process that is covered, in whole or in part, by
an issued, valid, unexpired claim or a pending claim contained in the Patent
Rights in the country in which such product or pan thereof is made, used,
leased, offered for sale sold or imported; or

             (c) incorporates any Licensee Patent Rights Improvement.

         1.6 "Licensed Territory" shall mean China, Hong Kong and Taiwan.

         1.7 Licensor improvement" shall mean any invention, discovery,
enhancement or improvement arising out of or resulting from use of the Patent
Rights which is or may be patentable or otherwise protected under law made by
one or more employees or subcontractors of Licensor.

         1.8 "Licensor Information" shall mean any and all materials, technical
information, data, know-how and other infix-motion developed or created prior to
the Effective Date of this Agreement and provided to Licensee by Licensor after
the Effective Date and pertaining to the Patent Rights whether or not it is of a
confidential nature: but specifically not including the Software: provided
however, that such transfer shall not exceed three (3) hours of Licensor's time
and effort.

         1.9 "Net Sales" shall mean the gross sales revenues and fees billed by
Licensee or its Sublicenses, for the sale of Licensed Products, less the sum of
(1) amounts actually allowed or credited on returns or rejections of Licensed
Products; (2) value added taxes or use taxes, tariffs, import/export duties, and
other excise taxes imposed upon particular sales; and (3) shipping, handling,
transportation and insurance charges. In computing Net Sales, (1) no deductions
from gross revenues and fees shall be made for commissions paid to individuals
or entities, whether they be with independent sales agencies or regularly
employed on the payroll by Licensee or its Sublicenses, or for cost of
collections, and (2) Licensed Products will be considered sold when billed out
or invoiced. whichever is first.

         1.10 "Patent Rights" shall mean Licensor's rights in any patents and
patent applications and any patents issued from said applications and any
divisionals, continuations. continuations-in-part, re-examinations, and reissues
of said applications: and any foreign equivalents or patents issuing thereon.
Patents and applications contained within the Patent Rights are listed in
Exhibit A, as may be amended from time to time.

                                       2

<PAGE>

         1.11 "Patent Rights Linker" shall mean any linking carrier between a
core of a microparticle and the therapeutic agent, that consists of the subject
matter claimed in the Patent Rights as of the Effective Date.

         1.12 "Software" shall mean any and all software and related
documentation developed by Licensor and/or its suppliers and agents for use in
conjunction with the Patent Rights or the Licensed Products.

         1.13 "Sublicensee" shall mean any person or entity to which License
sublicenses any or all of the rights granted to Licensee under the terms and
conditions of this Agreement.

         1.14 "University of Maryland Agreement" shall mean that agreement
between Licensor and the University of Maryland, Baltimore, dated as of
September 16, 2003, under which the Patent Rights are licensed to Licensor.

2.  License Grant.

         2.1 Subject to certain rights which may be held by the United States
Government and certain rights reserved by the University of Maryland, Baltimore
with respect to research, leaching and non-commercial purposes, during the Term
of this Agreement. Licensor hereby grants to Licensee an exclusive,
non-transferable, sublicensable (in accordance with Section 12 herein) right and
license, solely in the Licensed Territory and the Licensed Field of Use, (i)
under the Patent Rights and the Licensee Patent Rights improvements to make,
have made, sell, lease, offer for sale, and import the Licensed Products, and
(ii) to use the Licensor Information solely in connection with the Licensed
Products.

         2.2 During the Term of this Agreement and subject to the terms and
conditions of this Agreement, Licensee may sublicense the rights granted
hereunder to its Sublicensees consistent with, and at least as restrictive as,
the terms and conditions of this Agreement.

                 2.2.1 Licensee agrees that any sublicenses granted by Licensee
shall contain such provisions as are necessary for Licensee to meet its
obligations under this Agreement and to reasonably protect the interests of
Licensor with regard to such sublicense.

                 2.2.2 Within fourteen (14) days following execution, Licensee
agrees to forward to Licensor a copy of any and all fully executed sublicense
agreements executed hereunder, provided that such agreements may be redacted
with respect to terms and conditions not applicable to the subject matter of
this Agreement. Licensee shall also deliver a copy of all applicable reports
received by Licensee from Sublicensees under the sublicenses as shall be
pertinent to a royalty accounting under such sublicense agreements: provided
that such copies may be redacted with respect to terms and conditions not
applicable to the subject matter of this Agreement.

                 2.2.3 Licensee shall not accept or receive from any Sublicense
anything of value in lieu of cash in consideration for any sublicense or other
transfer of Patent Rights or Licensed Products, that has any effect on any
royalty or other payments due under this Agreement or on the determination of

                                       3

<PAGE>

the value of the Net Sales of the Licensee or any Sublicensee, without
Licensor's prior written approval, which approval shall not be unreasonably
withheld, delayed or conditioned. In any event, Licensor shall provide such
approval, or notice of its decision not to provide such approval, within
fourteen (14) business days following Licensee's requesting such approval.
Licensee shall promptly give written notice to Licensor of Licensee's acceptance
or receipt from any Sublicensee of anything of value in lieu of cash in
consideration for any sublicense or other transfer of Patent Rights or Licensed
Products not requiring Licensor's approval under this Section 2.2.3.

                 2.2.4 Upon termination of this Agreement for any reason, all
sublicenses that are granted by Licensee to a Sublicensee pursuant to this
Agreement will remain in effect and Licensee shall cause such Sublicensee to
agree in writing to be bound by all applicable terms and conditions of this
Agreement, except those previously completely fulfilled by Licensee. For
clarity, Licensor will not be bound to perform any duties or obligations set
forth in any sublicenses that extend beyond the duties and obligations of
Licensor set forth in this Agreement. Any sublicense granted by Licensee shall
include provisions corresponding to those of this Section 2.2.4 with respect to
termination and the conditions of continuance of sublicenses.

         2.3 The license granted hereunder shall not be construed to confer any
rights upon Licensee by implication, estoppel, or otherwise, other than as
specifically set forth in this Agreement. Any rights not expressly granted under
this Agreement by Licensor to Licensee are hereby reserved by Licensor.

3. Intellectual Property Rights.

         3.1 Licensee acknowledges and agrees that Licensor shall own all right,
title and interest in and to all Licensor Improvements. Licensee further
acknowledges that Licensor shall own all right, title and interest in and to any
and all Licensee Patent Rights Improvements. Accordingly, Licensee shall assign
to Licensor all right, title and interest of Licensee to and under any and all
intellectual property rights in any and all Licensee Patent Rights Improvements.
Licensee shall promptly disclose the Licensee Patent Rights Improvements to
Licensor in writing within forty-five (45) days of their development. Licensee
agrees to execute any and all documents and other instruments and to do all
things reasonably requested by Licensor to vest Licensor with all right, title
and interest in and to the Licensee Patent Rights Improvements, other than those
rights explicitly granted under this Agreement.

         3.2 Licensor acknowledges and agrees that Licensee shall own all right,
title and interest in and to any and all Licensee improvements. Licensee shall
promptly disclose the Licensee Improvements and all related information
necessary for Licensor's review in writing to Licensor within forty-five (45)
days of their development. Licensor shall have the first option to enter into a
license agreement with Licensee for such Licensee Improvement and any and all
associated materials, technical information, data, know-how and other
information for the purposes of selling products incorporating such Licensee
Improvement anywhere in the world. Licensor may exercise such option by
providing written notice to Licensee within ninety (90) days following
licensor's receipt of Licensee's written notice of such Licensee Improvement

                                       4

<PAGE>

and the related materials identified above. Such license agreement shall include
terms and conditions mutually agreeable to the parties. Licensee shall use best
efforts to take such actions, including filing of patent applications,
consummate with the rights granted, in order to protect licensee's rights in the
Licensee Improvements.

         3.3 Upon written notice by Licensor to Licensee, the parties agree that
they shall negotiate in good with to grant access to Licensor to the clinical
data developed by Licensee.

         3.4 Except as expressly set forth herein. nothing in this Agreement is
intended to grant any rights to either party under any patent or copyright of
the other party, nor shall this Agreement grant any party any rights in or to
the Confidential Information (as defined in Section 7) of the other party.

4.  Licensee Responsibilities.

         4.1 Licensee shall use its best efforts to bring one or more Licensed
Products to market in the Licensed Territory through a thorough and diligent
program for exploitation of the Patent Rights in the Licensed Territory and
Licensed field or Use. Licensee's Rights shall satisfy the Following milestones:

                 (a) Within ninety (90) days following the Effective Date,
Licensee shall deliver to Licensor a commercially reasonable research and
development plan (the "R &D Plan"), showing the amount of money and time
budgeted and planned the technical development of the Patent Rights and a
proposed commercialization scheme for the Licensed Products within the Licensed
Territory and the Licensed Field of Use.

                 (b) Licensee shall provide quarterly written reports at the end
of each calendar quarter during the Term to Licensor on progress against the R&D
Plan, including without limitation, information on the research and development
activities related to the Licensed Products and marketing analyses, and any
commercially reasonable changes in the R&D Plan, which shall be made at
Licensee's discretion.

                 (c) Licensee shall commence development of a Licensed Product
and shall employ at least three (3) full-time persons on such development not
later than December 31, 2006. Such persons shall be reasonably trained and
skilled in development efforts related to the Licensed Products and the Patent
Rights.

                 (d) Licensee shall provide written notice to Licensor of the
categorization of its first Licensed Product by the Chinese regulatory authority
as a medical device or a pharmaceutical within seven (7) days of learning of
such classification.

                 (e) In the event that the first Licensed Produce is a medical
device. License Shall:

                                       5

<PAGE>

                    (i) initiate human clinical trials of such Licensed Product
not later than June 1, 2008; and

                    (ii) have commercially available for sale such Licensed
Product within the Licensed Territory and the Licensed Field of Use not later
than December 31. 2010.

                 (f) In the event that the first licensed Product is a
pharmaceutical. License shall:

                    (i) initiate human clinical trials of such Licensed Product
not later than July 1, 2010; and (ii) have commercially available for sale such
Licensed Product within the Licensed Territory and the Licensed Field of Else
not later than December 31. 2013.

         4.2 Licensee shall ensure that "Patent Pending" or the Patent Rights
patent number or both appears on all Licensed Products, their labels or their
packaging to the extent necessary to secure the enforceability of the Patent
Rights under applicable law.

         4.3 Licensee's failure to satisfy the requirements of this Section 4
shall be grounds for Licensor to either (i) convert Licensee's exclusive license
grant hereunder to a non-exclusive license grant or (ii) terminate this
Agreement in accordance with the terms of Section 14.4 herein. Licensor may
convert the exclusive license grant to a non-exclusive license grant, for lack
of diligence under Section 4.1 herein, upon thirty (30) days' prior written
notice to Licensee and Licensee's failure to cure such breach within such thirty
(30) day period.

5.  Fees and Royalties.

         5.1 In consideration of the rights and license granted hereunder.
License shall pay fees and royalties to Licensor in the manner provided
hereunder

                 (a) On the Effective Date, Licensee shall pay to Licensor a
non-refundable license fee of Ten Thousand Dollars ($10,000).

                 (b) Licensee shall pay to Licensor an annual License
maintenance fee of Two Thousand Dollars ($2.000) which shall he due and payable
on each anniversary of the Effective Date (the "Maintenance Fee").

                 (c) Licensee shall pay the following milestone payments;

                              i) Upon licensee's initiation of human clinical
                    trials or production of human data with respect to the first
                    Licensed Product to reach that stage of development,
                    Licensee shall pay to Licensor Five Thousand Dollars
                    ($5.000); and

                                       6

<PAGE>

                              (ii) Upon the first grant of regulatory approval
                    with respect to the first Licensed Product to receive a
                    regulatory approval under this Agreement. licensee shall pay
                    to Licensor Fifty Thousand Dollars ($50,000).

                 (d) Licensee shall pay a running royalty equal to three percent
(3%) of the Net Sales of Licensed Products: provided however, that for sales
between Licensee and its Sublicensees, the royalty for Net Sales of Licensed
Products shall he paid only with respect to the sales of such Sublicensee.
Commencing with the calendar year in which the First Commercial Sale occurs, the
Maintenance Fees for such calendar year shall be credited against the running
royalty fees for such calendar year. Such royalty payments shall be due and
payable within sixty (60) days of the end of the calendar quarter in which they
are incurred and shall be accompanied with the applicable report in accordance
with the requirements of Section 6 herein. If no royalty is due for any
quarterly period, Licensee shall so report.

                 (e) Royalties are payable from the country in which they are
earned and are subject to foreign exchange regulations then prevailing in the
country. Royalty payments must be paid to Licensor in United States Dollars in
cash or by check or wire transfer of immediately available funds. To the extent
sales may have been made by licensee and/or its Sublicensees in a foreign
country, those royalties will he determined first in the currency of the country
in which the royalties are earned, and then converted to their equivalent in
United States Dollars. The buying rates of exchange for converting the
currencies involved into the currency of the United States quoted by the Morgan
Guaranty Trust Company of New York, New York, averaged on the last business day
of each of three (3) consecutive calendar months constituting the quarterly
period in which the royalties were earned, will be used to determine any such
conversion. Licensee will bear any loss of exchange or value or pay any expenses
incurred in the transfer or conversion to United States Dollars.

                 (f) To the extent that statutes, laws, codes, or government
regulations (including currency exchange regulations) prevent or limit royalty
payments to Licensor by Licensee or its Sublicensces with respect to Net Sales
received in any country, Licensee shall render to Licensor quarterly reports of
Net Sales of Licensed Products in such country. All monies due and owing to
Licensor as provided in such quarterly reports at Licensors option (1) shall be
deposited promptly by Licensee or its Sublicensees, as the case may be in a
local bank in such country in an account to be designated by Licensor in
writing, or (2) will he paid promptly to Licensor or deposited in its account,
as directed in writing by Licensor in any other country where the payment or
deposit is lawful under the currency restrictions. For clarity, "promptly" as
used in this subsection 5.1(f) shall mean in accordance with the timing set
forth in Section 5.1(d).

                 (g) In the event of stacking royalties where licensee
determines that it is necessary to pay additional royalties to other parties or
Licensor in order to produce a Licensed Product, and the sum of royalties to be
paid by Licensee to all parties would exceed ten percent (10%) of Net Sales,
Licensee may deduct such amount owing to such third parties (prior to any
reductions) from the royalty owing to Licensor for the sale of such License
Products pursuant to Section 5.1(d) above. Notwithstanding the foregoing
provisions of this Section 5.1(g), in no event shall the royalties due to
Licensor pursuant to Section 5.1(d) above be so reduced to less than fifty
percent (50%) of the amount that would otherwise he due Licensor thereunder.

                                       7

<PAGE>

                 (h) All amounts not paid when due shall accrue interest daily
at the lesser of a monthly rate of one and one-half percent (1.5%) or the
highest rate permissible by law on the unpaid balance as calculated from the
date such amount is due until paid in full

6. Reports and Records.

         6.1 Licensee shall keep, and shall cause its Sublicensees to keep,
full, true and accurate books of account containing all particulars that may be
necessary for the purpose of showing the amounts payable to Licensor hereunder,
and said books and the supporting data shall be open, to the extent allowable by
applicable law, during business hours upon five (5) business days notice for
three (3) years following the end of the calendar year to which they pertain, to
the inspection of Licensor or its agents, no more frequently than semi-annually,
for the purpose of verifying Licensee's royalty statement or compliance in other
respects with this Agreement (the "Audit"). This obligation to maintain accurate
books of account and the right to inspect them shall survive termination of this
Agreement. Licensee may submit a new statement correcting an unintentional and
newly discovered overpayment within one hundred twenty (120) days after the
close of Licensee's corporate fiscal year in which the original payment was due.
Licensee's sole remedy for overpayment is credit against future payments due to
Licensor hereunder, unless such overpayment is made on the last payment due
under this Agreement, in which case Licensor shall reimburse such overpayment to
Licensee within sixty (60) days of receipt of the new statement.

         6.2 Licensee, within sixty (60) days after the end of each calendar
quarter, shall deliver to Licensor true and accurate reports, giving such
particulars of the business conducted by Licensee and its Sublicensces during
the preceding three (3) month period under this Agreement as shall be pertinent
to a royalty accounting hereunder, including without limitation: (a) number of
Licensed Products manufactured and sold by Licensee and by each Sublicensee; (b)
total billings for Licensed Products sold by Licensor and by, Sublicensee; (c)
accounting for all Licensed Products used or sold; and (d) names and addresses
of all Sublicensees of Licensee. In the event that the Audit shows an
underpayment, Licensee shall pay licensor the amounts underpaid. In addition, in
the event the Audit shows an underpayment or more than five percent (5%) for any
calendar quarter, Licensee shall pay Licensor, in addition to the amounts
underpaid, costs of the Audit and interest on the underpayment at an annual rate
of five percent (5%).

7. Confidentiality.

         7.1 For purposes of this Agreement "Confidential Information" means any
trade secrets or confidential or proprietary information whether in written,
digital, oral or other form which is unique, confidential or proprietary to the
disclosing party, its suppliers or agents (the "Disclosing Party"), which is
disclosed to the receiving party (the "Receiving Party"), including without
limitation, ideas, technical data, specifications, know-how, product manuals,

                                       8

<PAGE>

data sheets, sales, and technical bulletins, customer lists and contacts,
pricing information, sales and other financial information, marketing
information and techniques and any other materials or information related to any
aspect of the business or activities of the Disclosing Party which are not
generally known to others engaged in similar businesses or activities.
Notwithstanding the foregoing, Confidential Information shall not include
information that: (i) is or becomes generally known to the public not as a
result of a disclosure by the Receiving Party; (ii) is rightfully in the
possession of the Receiving Party without an obligation of confidentiality prior
to disclosure by the Disclosing Party; (iii) is received by the Receiving Party
in good faith and without restriction from a third party not under a
confidentiality obligation to the Disclosing Party and having the right to make
such disclosure; or (iv) is independently developed by the Licensee without
using the Confidential Information. The Disclosing Party's failure to mark any
Confidential Information as confidential, proprietary or otherwise shall not
affect its status as Confidential Information hereunder.

         7.2 The Receiving Party covenants and agrees, at all times during the
term of this Agreement and at all times thereafter: (i) that it will keep and
maintain all Confidential Information of the Disclosing Party in strict
confidence, using such degree of care as is appropriate to avoid unauthorized
use or disclosure, but in no case less than reasonable care: (ii) that it will
not, directly or indirectly, disclose any Confidential Information of the
Disclosing Party to anyone outside of the Receiving Party, except with the
Disclosing Party's prior written consent; (iii) that the Receiving Party will
not make use of any Confidential Information of the Disclosing Party for
purposes other than exercising its rights and fulfilling its obligations
hereunder or for the benefit of any third party or any entity other than the
Disclosing Party; (iv)that upon termination of this Agreement. or at any time
the Disclosing Party may so request, the Receiving Party will deliver promptly
to the Disclosing Party, or, at Disclosing Party's option, will destroy, all
memoranda, notes, records, reports, media and other documents and materials and
all copies thereof regarding or including any Confidential information of the
Disclosing Party which the Receiving Party may then possess or have under its
control; and (v) that the Receiving Party will take no action with respect to
the Confidential Information of the Disclosing Party that is inconsistent with
its confidential and proprietary nature. If the Receiving Party is required by
law to disclose any Confidential Information, the Receiving Party shall notify
the Disclosing Party in writing in advance of such disclosure, and provide the
Disclosing Party with assistance in obtaining an order protecting the
information from public disclosure and with copies of any related information so
that the Disclosing Party may take appropriate action to protect the Disclosing
Party's Confidential Information.

         7.3 The Receiving Party shall be permitted to disclose the Disclosing
Party's Confidential Information only to its employees, subcontractors and
agents ("Employees") having a need to know such information in connection with
this Agreement. The Receiving Party shall instruct all Employees as to their
obligations under this Agreement, and shall obtain from such Employees their
written acknowledgment and agreement to confidentiality terms and conditions no
less favorable to the Disclosing Party than this Agreement prior to their being
given access to the Disclosing Party's Confidential information. The Receiving
Party shall he responsible for all Employees' compliance with the terms of this
Agreement.

                                       9

<PAGE>

         7.4 The Receiving Party acknowledges that the disclosure of the
Disclosing Party's Confidential Information may cause irreparable injury to the
Receiving Party and damages which may be difficult to ascertain. In the event of
the actual or threatened disclosure of the Disclosing Party's Confidential
Information, the Receiving Party shall, in addition to any other rights or
remedies, be entitled to injunctive relief to protect and recover the Disclosing
Party's Confidential Information. The Receiving Party shall not object to the
entry of an injunction or other equitable relief against the Receiving Party on
the basis of an adequate remedy at law, lack of irreparable harm or any other
reason. The Receiving Party shall advise the Disclosing Party immediately in the
event that it learns or has reason to believe that any person or entity which
has had access to the Disclosing Party's Confidential Information has violated
or intends to violate the terms of this Agreement.

8. Insurance.

During the Term, Licensee shall procure and maintain commercially adequate
insurance coverage with respect to its business operations in fulfilling its
obligations hereunder. As applicable under local law, Licensee shall promptly
provide to Licensor certificates from the insurers indicating the names and
addresses of the insurance carriers, the amount of insurance coverage, the
nature of such coverage, and the expiration dates of each applicable

9. Representations and Warranties.

         9.1 Licensee represents and warrants to Licensor that (i) it has all
requisite power and authority to enter into and perform its obligations under
this Agreement: (ii) the execution, delivery and performance of this Agreement
is within its power and has been duly authorized by all necessary actions: (iii)
Licensee shall comply in all respects with all applicable laws, statutes,
regulations, ordinances and other rules: and (iv) to Licensee's knowledge, any
and information provided by Licensee to Licensor as of the Effective Date is
truthful and accurate. LICENSEE DISCLAIMS ALL OTHER WARRANTIES OF ANY KIND,
EXPRESS, IMPLIED OR STATUTORY, INCLUDING WITHOUT LIMIITATION, IMPLIED WARRANTIES
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT AND
PATENT VALIDITY.

         9.2 Licensor represents and warrants to Licensee that it: (i) it owns
all rights necessary to grant the License set forth in this Agreement: (ii) it
has requisite power and authority to enter into and perform its obligations
under this Agreement: (iii) the execution, delivery and performance of this
Agreement is within its power and has been duly authorized by all necessary
actions; (iv) Licensor shall comply in all respects with all applicable laws,
statutes, regulations, ordinances and other rules: (v) it does not own any
rights in any patent or patent application outside of the Patent Rights, the
claims of which would dominate a claim of a patent or patent application within
the Patent Rights: (vi) to Licensor's actual knowledge, it has not previously
granted any rights or licenses in conflict with the rights and licenses granted
herein: (vii) to Licensor's actual knowledge, no action, suit or claim has been
initiated and threatened against Licensor with respect to the Patent Rights or
its right to enter into and perform its obligations under this Agreement; (viii)
Licensor has provided to Licensee a true, correct and complete copy of the
University of Maryland Agreement, to the extent the same would limit Licensee's
rights hereunder or require any payment by licensee; (ix) in Licensor's

                                       10

<PAGE>

knowledge the University of Maryland Agreement is in full force and effect; (x)
as of the Effective Date, to Licensors actual knowledge, neither Licensor, nor
the University of Maryland is in breach of any provision of the University of
Maryland Agreement, and Licensor has neither given to, nor receive from, the
University of Maryland notice of such breach: and (xi) to Licensors actual
knowledge, any and all information provided by Licensor to Licensee as of the
Effective Date is truthful and accurate. LICENSOR DISCLAIMS ALL OTHER WARRANTIES
OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING WITHOUT LIMITATION,
IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
NON-ENFRINGEMENT AND PATENT VALIDITY.

10. Limitation of Liability.

EXCEPT FOR ITS CONFIDENTIALITY OBLIGATIONS AND ITS INDEMNIFICATION OBLIGATIONS
UNDER THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER
PARTY FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT
LIMITATION, INDIRECT, SPECIAL, PUNITIVE, OR EXEMPLARY DAMAGES FOR LOSS OF
BUSINESS, LOSS OF PROFITS, BUSINESS INTERRUPTION, OR LOSS OF BUSINESS
INFORMATION) ARISING OUT OF THIS AGREEMENT OR FOR ANY CLAIM BY ANY OTHER PARTY,
EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT
FOR ITS CONFIDENTIALITY OBLIGATIONS AND ITS INDEMNIFICATION OBLIGATIONS UNDER
THIS AGREEMENT, EACH PARTY'S AGGREGATE LIABILITY IN CONNECTION WITH AGREEMENT,
WHETHER IN CONTRACT OR TORT OR OTHERWISE, SHALL NOT EXCEED TWO (2) TIMES THE
AMOUNTS PAID TO LICENSOR UNDER TH1S AGREEMENT.

11.  Indemnification.

         11.1 Licensee shall indemnify, defend and hold harmless Licensor and
its directors, officers, employees, agents and representatives from and against
any and all third party claims, losses, damages, liabilities, costs and
expenses, including reasonable attorneys' fees, that arise out of, result from
or are related to (i) a breach by Licensee of any warranty, representation or
covenant set forth herein. (ii) Licensee's negligence or willful misconduct,
(iii) the possession, use or operation of the Patent Rights, the Licensor
Information, the Licensed Products and the Licensee Patents Rights Improvements
by Licensee, and (iv) death of, or injury to, any persons or damage to any
property arising out of or related to the manufacture, sale or improper use of
the Licensed Products by Licensee, its employees or agents.

         11.2 Licensor shall indemnify, defend and hold harmless Licensee and
its directors, officers, employees, agents and representatives from and against
any and all claims, losses, damages, liabilities, costs and expenses, including
without limitation reasonable attorneys` Fees, that arise out of, result from or
are related to (i) Licensor's breach of any warranty, representation or
obligation under this Agreement, and (ii) Licensors negligence or willful
misconduct.

         11.3 If any party entitled to indemnification under this article (an
".Indemnified Party") makes an indemnification request to the other, the
Indemnified Party shall permit the other party (the "indemnifying Party") to

                                       11

<PAGE>

control the defense, disposition or settlement of the matter at own expense;
provided that the Indemnifying Party shall not, without the consent of the
Indemnified Party, enter into any settlement or agree to any disposition that
imposes any conditions or obligations on the indemnified Party other than the
payment of monies that are readily measurable for purposes of determining the
monetary indemnification or reimbursement obligations of the Indemnifying Party.
The Indemnified Party shall notify the Indemnifying Party promptly of any claim
for which the Indemnifying Party is responsible and shall reasonably cooperate
with the Indemnifying Party to Facilitate defense of any such claim. An
Indemnified Party shall at all times have the option to participate in any
matter or litigation, including, but not limited to participation through
counsel of its own selection, if desired, the hiring of such separate counsel
being at Indemnified Party's own expense.

12.  Patent Prosecution.

         12.1 To the extent that Licensor has the right to file for, prosecute
or maintain the Patents Rights under the University of Maryland Agreement,
Licensor shall reasonably exercise such rights. Licensor shall keep Licensee
reasonably informed as to the status of the Parent Rights as they relate to the
Licensed Field of Use in the Licensed Territory. Licensee may provide to
Licensor comments concerning (i) the scope and content of all patent
applications and: (ii) content of and proposed responses to official actions of
the United Slates Patent and Trademark Office and foreign patent offices during,
the prosecution of any patent applications, in each case to the extent the same
are within the Patent Rights; and Licensor may, at its sole discretion, consider
incorporating Licensee's comments in such applications and responses. In the
event that Licensor elects to abandon a patent or application within the Patent
Rights, Licensee shall have the right to undertake the prosecution and
maintenance of such patent or application, at its own expense in the name of
Licensor (or the University of Maryland, Baltimore, if required under the
University of Maryland Agreement), provided the same has applicability within
the Licensed Field of Use in the licensed Territory. Licensor shall notify
Licensee of any election not to pursue the prosecution or maintenance of a
patent application or patent within the Patent Rights reasonably in advance of
any applicable deadlines.

13.  Infringement.

         13.1 The parties shall inform each other promptly, in writing, of any
alleged infringement of the Patent Rights in the Licensed Territory and the
Licensed Field of Use by a third party and any available evidence thereof.
Licensor and Licensee shall consort one another in a timely manner concerning
any appropriate response to the infringement.

         13.2 Licensee may prosecute such infringement at its own expense. If
requested by Licensee, Licensor will join in any legal actions enforcing or
defending the Patent Rights against third parties in the Licensed Territory
deemed necessary or advisable by Licensee to prevent or seek damages, or both,
from the infringement of the Patent Rights provided that Licensee funds all
costs associated with such actions, using counsel of Licensee's selection and
subject to Licensor's approval which may not he unreasonably withheld, and
indemnifies and holds Licensor harmless with respect to any claims or damages
trade against or sustained by Licensor in connection with such involvement. In
all cases, Licensee shall keep Licensor reasonably apprised of the status and
progress of any such litigation.

                                       12

<PAGE>

         13.3 Licensee shall not settle or compromise any such suit in a mariner
that would compromise Licensor's rights under this Agreement or the Patent
Rights without Licensee's prior written consent, which shall not be unreasonably
withheld. Subject to satisfying the obligations to Licensor under Section 13.2
herein, financial recoveries from any such litigation will he applied to
reimburse Licensee for its litigation expenditures. with any remaining or
additional recoveries being paid to Licensee, subject to a royalty due to
Licensor based on treatment as Net Sales in accordance with the provisions of
this Agreement.

         13.4 Licensee's rights under Section 13 of this Agreement are subject
to the continuing right of Licensor to intervene at Licensee's own expense and
join Licensee in any claim or suit for infringement of the Patent Rights.
Licensee and Licensor shall agree on the manner in which they shall exercise
control over such action. Licensor shall have the right to have its own counsel
if it so desired al its own expense. Financial recoveries from any such
litigation will first be applied to reimburse Licensee and Licensor for their
litigation expenditures with additional recoveries being first subject to a
royalty due to Licensor based on treatment as Net Sales in accordance with the
provisions of this Agreement and then shared between Licensor and Licensee in
proportion with their share of the litigation expenses in such infringement
action.

         13.5 If Licensee fails to prosecute any infringement within six (6)
months of notice of such infringement, Licensor may prosecute such infringement
al its own expense. In such event, financial recoveries will he entirely
retained by licensor.

         13.6 In any action to enforce any of the Patent Rights, either party,
at the request and expense of the other party shall cooperate to the fullest
extent reasonably possible at the requesting party's expense. This provision
shall not be construed to require either party to undertake any activities,
including legal discovery, at the request of any third party except as may be
required by lawful process of a court of competent jurisdiction.

14. Term and Termination.

         14.1 Unless sooner terminated as provided in this Section 14 or by
mutual written agreement of the parties, this Agreement shall continue in full
force and effect until the disallowance, expiration, or invalidation of the last
valid claim of the last Patent Right anywhere which is licensed under this
Agreement (the "Term").

         14.2 Licensor shall have the right to terminate this Agreement at any
time upon notice to Licensee upon any of the following events: (a) if Licensee
shall file in any court. pursuant to any statute either of the United States or
any state, a petition in bankruptcy or insolvency or for the appointment of a
receiver or trustee of all or substantially all of Licensee's property, or if
Licensee shall make an assignment for the benefit of creditors, or if Licensee
shall commit any other affirmative act of insolvency: or (b) if there shall be
filed against Licensee in any court. pursuant to any statute either of the
United States or any state, an involuntary petition in bankruptcy or insolvency
or for reorganization, or if there shall he involuntarily appointed a receiver
or trustee of all or substantially all of Licensee's property, unless such
petition or appointment is set aside or withdrawn or ceases to he in effect
within one hundred twenty (120) days of the date of the filing or the
appointment.

                                       13

<PAGE>

         14.3 In the event that Licensee fails to pay Licensor any royalties due
and payable hereunder, Licensor shall have the right to terminate this Agreement
on thirty (30) days' notice, unless Licensee shall pay to Licensor within such
thirty (30) day period, all amounts payable pursuant to this Agreement. Upon the
expiration of such thirty (30) day period, if Licensee shall not have paid all
such amounts payable pursuant to this Agreement, the rights, privileges and
license granted hereunder shall terminate.

         14.4 Upon any material breach or default of this Agreement by Licensee,
other than those occurrences set out in Sections 14.2 and 14.3 herein, Licensor
shall have the right to terminate this Agreement and the rights, privileges and
license granted hereunder upon thirty (30) days' written notice to Licensee and
Licensee's failure to cure such breach within such thirty (30) day period.

         14.5 Licensee shall have the right to terminate this Agreement at any
time upon ninety (90) days' prior written notice to Licensor, and upon payment
of all amounts due to Licensor Through the effective date of the termination.

         14.6 In the event of termination under this Section 14, Licensor shall
have the right, subject to additional terms to be negotiated in good faith by
the parties, to cross-reference and rely upon any approvals and use all data
submitted by Licensee to any regulatory agency in connection with Licensed
Products or any products covered under the Patent Rights that Licensor or its
other licensee's may seek approval on. Licensor shall bear all costs and
expenses related to the transfer of any such approvals and/or data. The parties
shall negotiate in good faith the terms under which Licensor may provide such
data to third parties.

         14.7 Upon expiration of this Agreement, but not upon the earlier
termination, the license granted to Licensee in Section 2 herein shall become
non-exclusive, fully paid-up and irrevocable.

         14.8 The following provisions shall apply upon termination or
expiration of this Agreement;

                    (i) each party shall return to the other party and
immediately cease all use of such other party's Confidential Information
previously furnished by such other party and then in the possession or under the
control of such party;

                    (ii) all indebtedness of Licensee to Licensor shall become
immediately due and payable without further notice and demand, which is hereby
expressly waived, and each party shall pay to the other party an and amounts due
to such party through the date of termination or expiration of this Agreement.

15. Non-solicitation.

During the Term of this Agreement, and for a period of two (2) years following
the termination or expiration of this Agreement, each party agrees that: (1) it
shall not hire, solicit, cause or induce any employee, sales representative,
contractor or consultant of the other party to terminate his or her relationship
or employment with such party: and (ii) it shall not solicit, cause or induce
any customer of the other party not to do business with such party.

                                       14

<PAGE>

16. Export Restrictions.

This Agreement is expressly made subject to any applicable laws, regulations,
orders, or other restrictions on the import and export of the technology related
to or information about the Patent Rights, Licensor Information, Licensed
Products, Licensee Patent Rights improvements and other rights under this
Agreement which may be imposed from time to time. Licensee agrees that it shall
comply, and cause its Sublicensees to comply, with any such import or export
applicable laws, regulations, orders, or other restrictions. Licensee agrees to
indemnify and hold harmless, Licensor against all claims, losses, damages,
liabilities, costs and expenses, including reasonable attorneys' fees, to the
extent such claims arise out of any 'breach of this Section 16,

17, Dispute Resolution.

If a dispute between the parties related to this Agreement arises, the parties
hereby agree to attempt to resolve such dispute by good faith negotiations
within thirty (30) days after notice from the other party is received. In the
event that the parties are not able to resolve the dispute within such thirty
(30) day period, or any agreed extension, the parties shall confer in good faith
with respect to the possibility of resolving the matter through mediation with a
mutually acceptable third party or a national mediation organization. The
parties agree that they will participate in any mediation sessions in good faith
in an effort to resolve the dispute in an informal and inexpensive manner. All
expenses of the mediator will he shared equally by the parties. Any applicable
statute of limitations will be tolled during the pendency of a mediation
initiated under this Agreement. Evidence of anything said or any admission made
in the course of any mediation will not be admissible in evidence in any civil
action between the parties. In addition, no document prepared for the purpose
of, or in the course of or pursuant to, the mediation, or copy thereof will be
admissible in evidence in any civil action between the parties. However, the
admissibility or evidence shall not be limited if all parties who participated
in the mediation consent to disclosure of the evidence.

18. Publicity.

Except for disclosures which Licensor, in its sole discretion, deems necessary
to satisfy reporting and other requirements under applicable securities laws and
any other applicable laws and us otherwise set forth herein, neither party shall
make public statements or announcements with respect to this Agreement without
the prior written consent of the other party, which may not be unreasonably
withheld. Licensee acknowledges that summaries or descriptions of reports to
governmental agencies are announced to the public through press releases or
other means. Upon execution of this Agreement and during the Term, Licensee
acknowledges that Licensor shall from time to time issue press releases under
this Agreement and agrees to provide any and all information reasonably
requested by Licensor in connection with such press releases, including without
limitation, a brief description of Licensee, its business and its principals.
Licensor shall promptly provide written notice to Licensee of such filings and
press releases that involve Licensee.

19. Termination of Prior Agreements and Release.

The parties agree that the Confidentiality and Non-Disclosure Agreement dated
May 5. 2005 by and between Licensee and Licensor and the Letter Agreement dated
August 7, 2005 by, and between the Licensee and the Licensor are hereby

                                       15

<PAGE>

terminated and of no further force or effect. Each party, for itself and its
past, present and future parents, subsidiaries, successors and assigns, and
their respective officers, directors, stockholders, members, partners, agents,
attorneys, representatives and employees (separately and collectively, the
"Releaser"), does hereby irrevocably and unconditionally release, exonerate and
forever discharge the other party hereunder, its past, present and future
parents, subsidiaries, successors and assigns, and their respective officers,
directors, stockholders, members, partners, agents, attorneys, representatives
and employees (separately and collectively, the "Release"), of and from any and
all actions, causes of action, suits, debts, dues, sums of money, accounts,
claims, demands, damages, costs and expense's, attorneys' fees, obligations,
liabilities and judgments, or whatever kind or nature, known or unknown,
disclosed or undisclosed, suspected, or unsuspected, in law or in equity or
otherwise (the "Claims"), that the Releasor ever had, now have, or can, shall or
may have, against the Releasee upon or by reason of any matter, cause, or thing
whatsoever prior to or upon the date of the execution of this Agreement, but
specifically excluding any Claims with respect to the terms and conditions of
this Agreement. This is a General Release.

20.  Miscellaneous.

        20.1 Licensee shall not assign its rights or delegate its duties under
this Agreement either in whole or in part without the prior written consent of
Licensor, except that Licensee shall have the right to assign this Agreement in
whole or in part as part of a corporate reorganization, consolidation, merger,
or sale of substantially all of its assets, or any other transfer of Licensee's
entire business or such part of License business that exercises all rights
granted under this Agreement upon written notice to Licensor. This Agreement may
he assigned by Licensor, upon notice to Licensee, to any party acquiring all or
any substantial portion of Licensor's business relating to the Patent Rights and
the Licensed Products, whether by asset purchase, stock purchase or merger. Any
attempted assignment or delegation without such consent will be void. This
Agreement shall bind and inure to the benefit or each party's successors and
permitted assigns.

         20.2 This Agreement, including the attached exhibits, constitutes the
entire agreement. superseding all prior oral or written agreements,
understandings, conditions and warranties, between the parties hereto on the
subject matter hereof, and may be modified or amended only by a writing signed
by both of the parties hereto.

         20.3 All notices under this Agreement shall he in writing and given by
registered mail or nationally recognized overnight courier service, addressed to
the parties at the addresses indicated above, or to such other address of which
either party may advise the other in writing. Notices will be deemed given when
received by the recipient.

         20.4 THE PARTIES AGREE THAT THIS AGREEMENT AND THE RELATIONSHIP BETWEEN
THE PARTIES SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF
THE, STATE OF MARYLAND OF THE UNITED STATES OF AMERICA. WITHOUT-REGARD TO ITS
PRINCIPLES OF CONFLICTS OF LAWS AND WITHOUT APPLICATION OF THE 1980 U.N.

                                       16

<PAGE>

CONVENTION ON CONTRACTS FOR THE INTERNATIONAL SALE OF GOODS AND OTHER
INTERNATIONAL LAWS. EXCEPT FOR THE DISPUTE RESOLUTION PROVISIONS SET FORTH TN
SECTION 17 HEREIN, THE PARTIES AGREE TO SUBMIT TO THE EXCLUSIVE JURISDICTION AND
VENUE OF THE FEDERAL AND/OR STATE COURTS TN THE STATE OE MARYLAND FOR THE
RESOLUTION OF ANY DESPUTES ARISING HEREUNDER.

         20.5 Licensee agrees that the failure of Licensor at any time to
require performance by licensor of any of the provisions herein shall not
operate as a waiver of the right of Licensor to request strict performance of
the same or like provisions, or any other provisions hereof, at a later time.
Any waiver of the provisions of this Agreement or of a party's rights or
remedies under this Agreement must be in writing, signed by the waiving party,
to be effective.

         20.6 The invalidity or unenforceability in whole or in part of any
provision of this Agreement shall not affect the validity and enforceability of
the remaining provisions which shall be read as if such invalid or unenforceable
provisions had never been included.

         20.7 The parties acknowledge and agree that any provision that by its
nature survives shall survive cancellation or termination of this Agreement.

         20.8 If either party brings an action to enforce the terms of this
Agreement, the prevailing party shall he entitled to recover all costs and
expenses, including attorneys' fees, from the other party.

         20.9 This Agreement may be executed in one or more counterparts, each
of which shall be deemed an original, and all of which together shall constitute
one and the same Agreement.

                  (REMAINDER OF PAGE LEFT INTENTIONALLY BLANK)

                                       17

<PAGE>

     IN WITNESS WHEREOF. each party hereby executes this Agreement, which may be
executed in counterparts, intending to be bound as of the date written above.

                                            JDA MEDICAL TECHNOLOGIES, INC.

                                            By:_______________________________
                                            Name:____________________________
                                            Title:______________________________

                                            FOUNTAIN PHARMACEUTICALS, INC.

                                            By: ______________________________
                                            Name:____________________________
                                            Title:_____________________________

                                       18

<PAGE>

                                    EXHIBIT A

                                 Patent Rights

 -------------------------------------------------------------------------------
Application No.      Filing Date       Country            Title
 -------------------------------------------------------------------------------
 -------------------------------------------------------------------------------
PCT/US04/019337        6/18104           PCT       Microparticles for
                                                   Microarterial Imaging and
                                                   Radiotherapy
 -------------------------------------------------------------------------------
 -------------------------------------------------------------------------------
200480016791.1        12/20/05            CN       Microparticles for
                                                   Microarterial Imaging and
                                                   Radiotherapy
 -------------------------------------------------------------------------------

                                       19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]